# Entecavir

## Baraclude 0.5mg

| TAH Drug Code      | [OBAR](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBAR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of chronic active type B viral hepatitis or reactivation of hepatitis B viral hepatitis in adults and children over 2 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive, compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to entecavir or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Gastrointestinal: Nausea (Adult, less than 1%; Pediatric, greater than 1% ) Neurologic: Dizziness (Less than 1% ), Headache (2% to 4% ) Other: Fatigue (1% to 3% ) Serious Endocrine metabolic: Lactic acidosis Hepatic: Hepatomegaly (Severe), With steatosis, Recurrent hepatitis                                                                                                                                                                                                                                                                                                                                                                  |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## 1mg BARACLUDE

| TAH Drug Code      | [OBAR1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBAR1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of chronic active type B viral hepatitis or reactivation of hepatitis B viral hepatitis in adults and children over 2 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive, compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to entecavir or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Gastrointestinal: Nausea (Adult, less than 1%; Pediatric, greater than 1% ) Neurologic: Dizziness (Less than 1% ), Headache (2% to 4% ) Other: Fatigue (1% to 3% ) Serious Endocrine metabolic: Lactic acidosis Hepatic: Hepatomegaly (Severe), With steatosis, Recurrent hepatitis                                                                                                                                                                                                                                                                                                                                                                  |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

